Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.

The Key to Connecting with Patients: Pharma's Market Access Transformation

How pharma can productively coexist with PBMs—and still lower drug costs faster.

Working with the Middle

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.

The Next Era of Drug Safety is in Intelligent Action

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - December 2025

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

Sector leaders explore how third-party logistics providers are adapting to advanced therapies, tighter regulations, digital transformation, and expanding cold chain demands.

Inside the Shifting Role of Pharma 3PLs: Resilience, Regulation, and the Road Ahead

Rising recalls, tighter FDA enforcement, global supply chain dependencies, and rapid technology shifts are reshaping pharmaceutical quality and compliance—forcing manufacturers to rethink oversight, resilience, and continuous improvement across operations.

Quality and Compliance in the Pharmaceutical Industry: Navigating a Transformed Landscape

As policy pressure, tariffs, and supply chain risks push drugmakers to expand US-based production, this FAQ explains what pharma reshoring is, why it’s accelerating, which companies are investing, and how the shift could reshape reliability, regulation, and patient access.

FAQ: What Domestic Manufacturing Means for Drug Supply Chains

Podcasts

In today’s Pharma Pulse, a telehealth giant retreats from the weight loss pill conflict, while safety-net hospitals secure a major legal victory against 340B reform.

Pharma Pulse: The GLP-1 Copycat Crackdown and the 340B Rebate Retreat

Managing partner at Numerof & Associates.

Community pharmacies are being squeezed out of local markets, creating pharmacy deserts that raise costs, reduce access, and strain the healthcare system.

The Broken Business Model Driving America’s Pharmacy Deserts

SQ Innovation’s at-home furosemide injection for heart failure–related edema is now available through two of the Big Three drug wholesalers and covered under a Medicaid rebate agreement, expanding access for hospitals, pharmacies, and eligible patients.

Lasix ONYU Gains Major Distributor Access Through Cardinal Health and Cencora

These hubs can streamline access, reduce friction across reimbursement and logistics, and improve outcomes, as the CGT pipeline expands and patient demand accelerates.

Designing Patient Hubs Purpose-Built for Cell and Gene Therapies

TrumpRx is meant to reduce drug costs, but Americans are wondering how it works and what impact it will have.

Everything to Know About TrumpRx in 2026

In today’s Pharma Pulse, TrumpRx officially goes live, while Novo Nordisk prepares to take the oral version of Wegovy to the biggest stage in advertising.

Pharma Pulse: TrumpRx Takes Flight and Novo Nordisk’s Super Bowl Gambit

What 2025 means for the life sciences sector in the New Year.

Featured Content

The Key to Connecting with Patients: Pharma's Market Access Transformation

Working with the Middle

The Next Era of Drug Safety is in Intelligent Action

Pharmaceutical Commerce - December 2025